Amygdala Neurosciences Acquires GS-6637 From Gilead Sciences

• 2.24.2017

On February 16, 2017, Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, announced that it entered into an agreement with Gilead Sciences, Inc. for the acquisition of GS-6637. GS-6637 is a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

WilmerHale is serving as legal counsel to Gilead on this transaction, with Eric Hwang leading the team that includes John Lee and Cindy Moon.

Read the full press release.